Latest news

• Tiziana completes enrolment of first patient cohort in MS expanded access programme

  Tiziana Life Sciences (Tiziana) has completed the enrolment of the first patient cohort in its intermediate size patient population expanded access programme to evaluate foralumab in non-active Secondary Progressive Multiple ... Sclerosis (SPMS),

• Tiziana starts enrolment in secondary progressive MS expanded access programme

  Tiziana Life Sciences (Tiziana) has announced the start of enrolment of the first patient cohort in its intermediate size patient population expanded access programme to evaluate foralumab in non-active secondary ... progressive multiple sclerosis (SPMS)

• Tiziana’s Foralumab shows promise in second patient with secondary progressive MS

  Tiziana Life Sciences (Tiziana) has announced that the second patient with non-active secondary progressive multiple sclerosis (SPMS) has shown ‘continued clinical improvement’ after six months of dosing with intranasal Foralumab.

• Tiziana announces Brigham and Women’s hospital will receive ALS Association grant

  an intranasal anti-CD3 monoclonal antibody (mAb) in an animal model of amyotrophic lateral sclerosis (ALS). ... Additionally, we are currently studying foralumab, the first entirely human anti-CD3 mAb, in patients with secondary progressive multiple

• Roche shares new positive Ocrevus data for MS patients

  Roche has shared new Ocrevus (ocrelizumab) data that demonstrates its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). ... Multiple sclerosis (MS) is a chronic